Orion Corporation: Managers’ transactions – Kari Jussi Aho
ORION CORPORATION
MANAGERS’ TRANSACTIONS
9 MARCH 2023 at 11.30 EET
Orion Corporation: Managers’ transactions – Kari Jussi Aho
Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
Orion Oyj - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Kari Jussi Aho
Position: Member of the Board/Deputy member
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 26870/7/10
____________________________________________
Transaction date: 2023-03-07
Venue: CEUD
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 2 Unit price: 44.375 EUR
(2): Volume: 75 Unit price: 44.4 EUR
Aggregated transactions (2):
Volume: 77 Volume weighted average price: 44.39935 EUR
____________________________________________
Transaction date: 2023-03-07
Venue: DHEL
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 6 Unit price: 44.35 EUR
Aggregated transactions (1):
Volume: 6 Volume weighted average price: 44.35 EUR
____________________________________________
Transaction date: 2023-03-07
Venue: TQEM
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 2 Unit price: 44.375 EUR
Aggregated transactions (1):
Volume: 2 Volume weighted average price: 44.375 EUR
____________________________________________
Transaction date: 2023-03-07
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 1 Unit price: 44.35 EUR
(2): Volume: 2 Unit price: 44.35 EUR
(3): Volume: 6 Unit price: 44.35 EUR
(4): Volume: 4 Unit price: 44.35 EUR
(5): Volume: 1 Unit price: 44.4 EUR
(6): Volume: 46 Unit price: 44.4 EUR
(7): Volume: 2 Unit price: 44.4 EUR
Aggregated transactions (7):
Volume: 62 Volume weighted average price: 44.38952 EUR
____________________________________________
Transaction date: 2023-03-08
Venue: BEUP
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 16 Unit price: 44.625 EUR
(2): Volume: 16 Unit price: 44.65 EUR
(3): Volume: 34 Unit price: 44.65 EUR
Aggregated transactions (3):
Volume: 66 Volume weighted average price: 44.64394 EUR
____________________________________________
Transaction date: 2023-03-08
Venue: CEUX
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 41 Unit price: 44.8 EUR
(2): Volume: 40 Unit price: 44.55 EUR
(3): Volume: 42 Unit price: 44.55 EUR
Aggregated transactions (3):
Volume: 123 Volume weighted average price: 44.63333 EUR
____________________________________________
Transaction date: 2023-03-08
Venue: DHEL
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 8 Unit price: 44.375 EUR
(2): Volume: 75 Unit price: 44.275 EUR
(3): Volume: 3 Unit price: 44.275 EUR
(4): Volume: 35 Unit price: 44.275 EUR
Aggregated transactions (4):
Volume: 121 Volume weighted average price: 44.28161 EUR
____________________________________________
Transaction date: 2023-03-08
Venue: TQEM
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 63 Unit price: 44.65 EUR
(2): Volume: 234 Unit price: 44.475 EUR
(3): Volume: 69 Unit price: 44.35 EUR
(4): Volume: 191 Unit price: 44.35 EUR
Aggregated transactions (4):
Volume: 557 Volume weighted average price: 44.43645 EUR
____________________________________________
Transaction date: 2023-03-08
Venue: TQEX
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 41 Unit price: 44.55 EUR
Aggregated transactions (1):
Volume: 41 Volume weighted average price: 44.55 EUR
____________________________________________
Transaction date: 2023-03-08
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 32 Unit price: 44.8 EUR
(2): Volume: 144 Unit price: 44.7 EUR
(3): Volume: 1 Unit price: 44.65 EUR
(4): Volume: 3 Unit price: 44.65 EUR
(5): Volume: 150 Unit price: 44.65 EUR
(6): Volume: 299 Unit price: 44.55 EUR
(7): Volume: 35 Unit price: 44.35 EUR
(8): Volume: 55 Unit price: 44.35 EUR
(9): Volume: 65 Unit price: 44.45 EUR
(10): Volume: 10 Unit price: 44.45 EUR
(11): Volume: 29 Unit price: 44.45 EUR
(12): Volume: 150 Unit price: 44.45 EUR
(13): Volume: 9 Unit price: 44.45 EUR
(14): Volume: 150 Unit price: 44.45 EUR
(15): Volume: 11 Unit price: 44.4 EUR
(16): Volume: 150 Unit price: 44.4 EUR
(17): Volume: 13 Unit price: 44.4 EUR
(18): Volume: 150 Unit price: 44.4 EUR
(19): Volume: 17 Unit price: 44.35 EUR
(20): Volume: 150 Unit price: 44.35 EUR
(21): Volume: 150 Unit price: 44.35 EUR
(22): Volume: 150 Unit price: 44.35 EUR
(23): Volume: 9 Unit price: 44.35 EUR
(24): Volume: 18 Unit price: 44.35 EUR
(25): Volume: 150 Unit price: 44.35 EUR
(26): Volume: 9 Unit price: 44.35 EUR
(27): Volume: 150 Unit price: 44.35 EUR
(28): Volume: 2 Unit price: 44.35 EUR
(29): Volume: 18 Unit price: 44.3 EUR
(30): Volume: 8 Unit price: 44.3 EUR
(31): Volume: 11 Unit price: 44.3 EUR
(32): Volume: 1 Unit price: 44.3 EUR
(33): Volume: 2 Unit price: 44.3 EUR
(34): Volume: 5 Unit price: 44.3 EUR
(35): Volume: 12 Unit price: 44.3 EUR
(36): Volume: 99 Unit price: 44.3 EUR
(37): Volume: 19 Unit price: 44.3 EUR
(38): Volume: 9 Unit price: 44.3 EUR
Aggregated transactions (38):
Volume: 2445 Volume weighted average price: 44.43961 EUR
Orion Corporation
| Liisa Hurme President and CEO | Olli Huotari SVP, Corporate Functions |
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Storaktionærmeddelelse25.3.2023 14:30:37 CET | pressemeddelelse
Årets meddelelse nr. 20 Dato: 25. marts 2023 Storaktionærmeddelelse Det skal herved meddeles, at Pharma Equity Group A/S har modtaget meddelelse om at NK Invest ApS ejerandel, både direkte og indirekte via dennes ejerskab af Selskabet af 25. marts DK ApS og Selskabet af 25. marts II ApS, efter kapitalforhøjelse offentliggjort under selskabsmeddelelse nr. 16 af 24. marts 2023, udgør mindre end 5 % af den udstedte aktiekapital i Pharma Equity Group A/S. Alle henvendelser vedrørende ovenstående bedes venligst rettet til direktør Peter Ole Jensen på e-mail: peter.ole.jensen@pharmaequitygroup.com. Med venlig hilsen Pharma Equity Group A/S På bestyrelsens vegne
FCB Tops 2023 WARC Rankings for Creative Effectiveness24.3.2023 21:41:59 CET | Press release
FCB awarded #1 Creative Agency & #1 Campaign for Effectiveness in WARC Effective 100 NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) -- FCB was a top performer in the 2023 WARC Rankings, earning recognition as the #1 Creative Agency for Effectiveness in the WARC Effective 100, among other distinctions. Numerous FCB campaigns were honored as well, including Michelob ULTRA’s “Contract for Change,” which ranked as the #1 Campaign for Effectiveness. “Creative is the business and the business is creative. To separate the two does a disservice to the industry. We will continue to partner with our clients to create work that is both effective in the moment and impactful long term. FCB is honored that this Timely and Timeless approach to work is being recognized by WARC,” said Susan Credle, FCB Global Chair & Global CCO. In the Effective 100, FCB New York was named the #1 Creative Agency for Effectiveness, joined by two additional FCB agencies, with FCB Chicago ranking #4 and FCB Toronto ranking #7,
Ordinary and Extraordinary General Meeting of April 12, 202324.3.2023 21:30:00 CET | Press release
Montrouge, France, March 24, 2023 Ordinary and Extraordinary General Meeting of April 12, 2023 Procedures for Obtaining Information and Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, will hold its Ordinary and Extraordinary General Meeting (the “General Meeting”) on April 12, 2023, at 10:00 a.m. CET at the Company’s headquarters located at 177-181 Avenue Pierre Brossolette – 92120 Montrouge, France. The preliminary notice (avis de réunion) containing the detailed agenda, draft resolutions as well as instructions to participate and vote for this General Meeting was published in the French “Bulletin des AnnoncesLégalesObligatoires (BALO)” dated March 8, 2023 (No. 2300429). The meeting notice (avis de convocation) was published in the French “Bulletin des AnnoncesLégalesObligatoires (BALO)” dated March 24, 2023 (No. 2300600) and in the legal newspaper Affiches pari
TGS: Approval of 2022 Financial Result24.3.2023 20:03:58 CET | Press release
Oslo, Norway (24 March 2023) – The Board of Directors of TGS ASA has today approved the financial statements for 2022. The financial statements were prepared in accordance with IFRS. Please see the attachment for a summary of changes from the preliminary annual accounts announced on 9 February 2023. About TGS TGS provides scientific data and intelligence to companies active in the energy sector. In addition to a global, extensive and diverse energy data library, TGS offers specialized services such as advanced processing and analytics alongside cloud-based data applications and solutions. For more information, visit TGS.com (http://www.tgs.com) or contact: Sven Børre Larsen CFO Tel: +47 90 94 36 73 E-mail: investor@tgs.com Attachment TGS Annual Accounts 2022 update
Nokia Corporation: Repurchase of own shares on 24.03.202324.3.2023 20:00:00 CET | Press release
Nokia Corporation Stock Exchange Release 24 March 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 24.03.2023 Espoo, Finland – On 24 March 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL306,0764.31CEUX7,3924.31AQEU2,6084.31TQEX6,3244.32Total322,4004.31 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and